Myers
Bristol Myers’ schizophrenia drug Cobenfy stumbles as adjunctive treatment, denting blockbuster plan
Cobenfy, Schizophrenia, Antipsychotic Agents, Adjunctive Orthodontic Procedure, Myers, Statistical Significance, Improvement, Single Agent Therapy
Bristol Myers says Camzyos fails Phase 3 study in genetic heart condition
Camzyos, Hypertrophic Cardiomyopathy, Myers, Hypertrophic cardiomyopathy without obstruction, Obstructed, Clinical Trials
The 5 Largest Biopharma Layoffs of Q1 2025: An Overview of Industry Restructuring
Biopharma layoffs 2025, Novartis layoffs, Galapagos layoffs, Bristol Myers Squibb layoffs, Merck cuts, Gilead workforce reduction, Q1 2025 job cuts, biotech restructuring, pharmaceutical industry job losses, industry trends.
Sotyktu Shows Promise in Phase 3 Psoriatic Arthritis Trial
Sotyktu, deucravacitinib, psoriatic arthritis, Bristol Myers Squibb, POETYK PsA-2 trial, TYK2 inhibitor
Bristol Myers Squibb’s Opdualag Fails Phase 3 Trial in Adjuvant Melanoma Treatment
Opdualag, Bristol Myers Squibb, melanoma, clinical trial failure, LAG-3 inhibitor, immunotherapy, adjuvant treatment
Bristol Myers Squibb Expands Cost-Cutting Measures and Streamlines Pipeline for Future Growth
Bristol Myers Squibb, cost-cutting, pipeline optimization, patent cliff, strategic restructuring, operational efficiency, pharmaceutical industry
Pharmaceutical Giants Bristol Myers Squibb and Kyowa Kirin Announce 119 Layoffs in New Jersey Amid Restructuring Efforts
Bristol Myers Squibb, Kyowa Kirin, layoffs, New Jersey, restructuring, pharmaceutical industry, cost-cutting, workforce reduction
Bristol Myers Squibb and Kyowa Kirin Announce New Rounds of Layoffs in New Jersey
Pharmaceutical layoffs, workforce reduction, cost-cutting measures, Bristol Myers Squibb, Kyowa Kirin, New Jersey pharma industry
Bristol Myers Squibb and Pfizer Unveil Promising Colorectal Cancer Treatments at ASCO GI 2025
Colorectal cancer, metastatic colorectal cancer, Bristol Myers Squibb, Pfizer, Opdivo, Yervoy, Braftovi, ASCO GI 2025, cancer treatment, immunotherapy.
Bristol Myers Squibb Marks Milestone with FDA Approval of Subcutaneous Opdivo Qvantig
Bristol Myers Squibb, Opdivo, subcutaneous administration, FDA approval, cancer treatment, immuno-oncology, PD-1 inhibitor.